Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: A qualitative preference study of patients and parents.
Landrum Peay H, Fischer R, Tzeng JP, Hesterlee SE, Morris C, Strong Martin A, Rensch C, Smith E, Ricotti V, Beaverson K, Wand H, Mansfield C. Landrum Peay H, et al. Among authors: fischer r. PLoS One. 2019 May 1;14(5):e0213649. doi: 10.1371/journal.pone.0213649. eCollection 2019. PLoS One. 2019. PMID: 31042754 Free PMC article.
The evolving role of patient preference studies in health-care decision-making, from clinical drug development to clinical care management.
Jackson Y, Janssen E, Fischer R, Beaverson K, Loftus J, Betteridge K, Rhoten S, Flood E, Lundie M. Jackson Y, et al. Among authors: fischer r. Expert Rev Pharmacoecon Outcomes Res. 2019 Aug;19(4):383-396. doi: 10.1080/14737167.2019.1612242. Epub 2019 May 9. Expert Rev Pharmacoecon Outcomes Res. 2019. PMID: 31070048 Review.
Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best-worst scaling experiment in caregivers and adult patients.
Paquin RS, Fischer R, Mansfield C, Mange B, Beaverson K, Ganot A, Martin AS, Morris C, Rensch C, Ricotti V, Russo LJ, Sadosky A, Smith EC, Peay HL. Paquin RS, et al. Among authors: fischer r. Orphanet J Rare Dis. 2019 May 9;14(1):102. doi: 10.1186/s13023-019-1069-6. Orphanet J Rare Dis. 2019. PMID: 31072340 Free PMC article.
Patients' and caregivers' maximum acceptable risk of death for non-curative gene therapy to treat Duchenne muscular dystrophy.
Peay HL, Fischer R, Mange B, Paquin RS, Smith EC, Sadosky A, Russo L, Ricotti V, Rensch C, Morris C, Martin AS, Ganot A, Beaverson K, Mansfield C. Peay HL, et al. Among authors: fischer r. Mol Genet Genomic Med. 2021 May;9(5):e1664. doi: 10.1002/mgg3.1664. Epub 2021 Mar 23. Mol Genet Genomic Med. 2021. PMID: 33755338 Free PMC article.
Development of a Clinical Global Impression of Change (CGI-C) and a Caregiver Global Impression of Change (CaGI-C) measure for ambulant individuals with Duchenne muscular dystrophy.
Staunton H, Trennery C, Arbuckle R, Guridi M, Zhuravleva E, Furlong P, Fischer R, Hall R. Staunton H, et al. Among authors: fischer r. Health Qual Life Outcomes. 2021 Jul 26;19(1):184. doi: 10.1186/s12955-021-01813-w. Health Qual Life Outcomes. 2021. PMID: 34311756 Free PMC article.
4,265 results